Supplement encyclopedia

Bifidobacterium longum

Bifidobacterium longum is a species of bifidobacteria used in supplements and some specially fortified foods. Labels such as BB536, 1714, and NCC3001 identify specific strains, or variants of the bacterium. Products can contain live bacteria or heat-inactivated cells.

Double-check the conclusions and review the sources before choosing a supplement.

Main conclusion

Potential benefits

  • Inactivated CLA8013 may slightly increase stool frequency in adults prone to constipation. Over two weeks, frequency increased by an average of 1.16 times per week versus 0.51 with placebo.
  • Strain 35624 may slightly relieve pain and discomfort in women with irritable bowel syndrome: an advantage over placebo was observed with 100 million CFU daily for four weeks.
  • Live ES1 and heat-treated HT-ES1 may reduce overall symptom severity in adults with irritable bowel syndrome and diarrhea. The overall symptom score decreased more than with placebo over 12 weeks.
  • In older people with chronic constipation, live BB536 showed no convincing advantage in the overall constipation score over four weeks.
  • NCC3001 may slightly relieve perceived stress in healthy adults with mild or moderate stress. Over six weeks, the stress score on a 0–56 scale was an average of 3.28 points lower than with placebo.
  • In adults with sleep complaints, strain 1714 showed no convincing advantage in the overall sleep score or wrist-device measures over eight weeks.

[1] [2] [3] [4] [5] [6]

What was studied

  • In adults with moderate or severe allergic rhinitis taking medicines, inactivated HT-ES1 improved the combined symptom and medication-use measure over eight weeks; live ES1 showed no convincing advantage.
  • In adults with overweight or obesity, BL21 showed no convincing additional reduction in body weight over eight weeks.
  • With severe illness or markedly weakened immunity, live probiotics may increase infection risk; agree on the choice of product with a doctor.

[1] [2] [3] [4] [5]

Forms studied

  • CLA8013 was studied in capsules containing heat-inactivated cells: 25 billion cell equivalents daily for two weeks. This is a count of cell equivalents, not CFU of live bacteria.
  • The stress study used live NCC3001 at 10 billion CFU daily for six weeks; the sleep study used live 1714 at 1 billion CFU daily for eight weeks.
  • On the package, look for the full strain code, CFU count at the end of shelf life, and storage conditions. Inactivated cells are listed as cell counts or cell equivalents.

[1] [2] [3] [4]

How to get it from food

  • B. longum is added to some specially fortified foods. In one study, the daily serving of yogurt with BB536 contained about 2 billion CFU of this strain.
  • When choosing yogurt, look on the package for the exact strain, amount per serving, and storage conditions. The words “live cultures” alone do not identify which strain is present.

[1] [2]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Bowel movement frequency — inactivated CLA8013Bowel movement frequency increased by 1.16 per week with CLA8013 versus 0.51 per week with placebo. The difference in change was 0.65 bowel movements per week (p = 0.048).
2/4 LowOne 2-week trial, with 104 of 120 participants included in the final analysis. People who responded strongly to placebo were excluded before group assignment, which limits how broadly the result applies to consumers.
1publicationEffects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study ↗120 adults aged 20–65 who were prone to constipation, of whom 104 were included in the final analysis
  1. Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study ↗
Bowel movement frequency — live BB536In week 2, participants averaged 5.38 bowel movements per week with BB536 versus 4.63 with placebo, a difference of 0.75 per week (p = 0.0334).
3/4 ModerateThe same 24 people received BB536 and placebo in separate periods, with a 4-week break between them. The result applies to these specific microcapsules and 2 weeks of use. Some participants did not have constipation.
1publicationIntegrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT ↗24 healthy adults aged 40–60 who had 3–5 or at least 7 bowel movements per week
  1. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT ↗
Digestive symptoms — inactivated HT-ES1After 8 weeks, the total GSRS-IBS digestive symptom score was 26.48 with HT-ES1 and 26.31 with placebo. The difference between groups was not statistically significant.
2/4 LowThe final analysis included 53 people and assessed a combined score for several bowel symptoms. This result does not provide a separate estimate of the effect on bloating.
1publicationEffect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study ↗60 healthy adults aged 18–65 with mild digestive symptoms, of whom 53 completed the regimen according to the protocol
  1. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

How to interpret bacterial counts
What to checkPractical guidance
Daily amountThere is no single official recommendation for all healthy people. Match the specific strain, amount, and duration of use to the relevant study.
Label on a product containing live bacteriaCheck the CFU count at the end of shelf life and the storage instructions. A higher count alone does not imply greater benefit.

Probiotics — Fact Sheet for Consumers (NIH ODS) ↗

Forms

Live bacteria. BB536, NCC3001, 1714, 35624, ES1, BL21, and APC1472 are distinct strains. Check the label for the full strain code, the CFU count at the end of shelf life, and storage instructions. A higher CFU count alone does not imply greater benefit. Inactivated cells. CLA8013 and HT-ES1 were heat-treated in these trials. Their doses are reported in cells or cell equivalents. These figures do not represent counts of live bacteria. Doses varied even for HT-ES1: 2.5 billion cells in the digestive studies and 2 billion cells in research on allergic rhinitis. Strain 35624. An early publication refers to it as B. infantis 35624. In the IBS pain trial, capsules providing 100 million CFU per day showed an advantage. That finding cannot be generalized to all doses or all B. longum products.

Guidance for each goal

Bowel movement frequency — inactivated CLA80132/4 LowRead moreCollapse
Confidence
2/4 LowOne 2-week trial, with 104 of 120 participants included in the final analysis. People who responded strongly to placebo were excluded before group assignment, which limits how broadly the result applies to consumers.

Bowel movement frequency increased slightly.

Study findings. Bowel movement frequency increased by 1.16 per week with CLA8013 versus 0.51 per week with placebo. The difference in change was 0.65 bowel movements per week (p = 0.048).

Studied regimen25 billion cell equivalents per day, taken as one capsule after dinnerCapsules containing heat-inactivated CLA8013
Duration and population2 weeks120 adults aged 20–65 who were prone to constipation, of whom 104 were included in the final analysis

Comparator — capsule with the same inactive ingredients and no CLA8013

Bowel movement frequency — live BB5363/4 ModerateRead moreCollapse
Confidence
3/4 ModerateThe same 24 people received BB536 and placebo in separate periods, with a 4-week break between them. The result applies to these specific microcapsules and 2 weeks of use. Some participants did not have constipation.

Bowel movements were slightly more frequent in week 2.

Study findings. In week 2, participants averaged 5.38 bowel movements per week with BB536 versus 4.63 with placebo, a difference of 0.75 per week (p = 0.0334).

Studied regimenAbout 5 billion CFU per day, taken as 0.53 g of microcapsules with waterLive BB536 in microcapsules with an acid-resistant coating
Duration and populationTwo 2-week periods separated by a 4-week break24 healthy adults aged 40–60 who had 3–5 or at least 7 bowel movements per week

Comparator — identical microcapsules containing potato starch and no BB536

Digestive symptoms — inactivated HT-ES12/4 LowRead moreCollapse
Confidence
2/4 LowThe final analysis included 53 people and assessed a combined score for several bowel symptoms. This result does not provide a separate estimate of the effect on bloating.

The overall symptom score did not improve compared with placebo.

Study findings. After 8 weeks, the total GSRS-IBS digestive symptom score was 26.48 with HT-ES1 and 26.31 with placebo. The difference between groups was not statistically significant.

Studied regimen2.5 billion cells per day, with 50 mg of the preparation in two capsules taken at breakfastCapsules containing heat-inactivated HT-ES1, strain CECT 7347
Duration and population8 weeks60 healthy adults aged 18–65 with mild digestive symptoms, of whom 53 completed the regimen according to the protocol

Comparator — capsules containing maltodextrin and no HT-ES1

IBS pain and discomfort — 356242/4 LowRead moreCollapse
Confidence
2/4 LowThe trial included only women with IBS and lasted 4 weeks. The 100 million CFU dose showed an advantage. The highest-dose capsule had formulation problems, and the results do not support a simple “more is better” rule.

At 100 million CFU, pain decreased slightly more than with placebo.

Study findings. Pain and discomfort scores on a 0–5 scale fell by 0.89 points with strain 35624 versus 0.58 points with placebo. The additional reduction was 0.31 points (p = 0.023).

Studied regimen100 million CFU per day in one capsule. The trial also tested 1 million and 10 billion CFU per day.Capsules containing dried live bacteria of strain 35624
Duration and population4 weeks362 women aged 18–65 with irritable bowel syndrome and varying bowel habits

Comparator — identical capsule without strain 35624

Symptoms of IBS with diarrhea — live ES12/4 LowRead moreCollapse
Confidence
2/4 LowOne trial of a specific strain in adults with IBS with diarrhea. The total score measures symptom severity. It does not show what proportion of participants recovered from IBS.

The overall symptom score decreased.

Study findings. The total IBS-SSS symptom score on a 0–500 scale fell by 173.70 points with live ES1 versus 60.44 points with placebo (p < 0.0001).

Studied regimen1 billion CFU per day, taken as two capsules togetherCapsules containing live ES1, strain CECT 7347
Duration and population84 days200 adults aged 18–65 with irritable bowel syndrome with diarrhea, of whom 197 had data after starting the regimen

Comparator — capsules containing maltodextrin and none of the bacteria under study

Symptoms of IBS with diarrhea — inactivated HT-ES12/4 LowRead moreCollapse
Confidence
2/4 LowThe result comes from one trial of the heat-treated preparation in adults with IBS with diarrhea. The dose and formulation differed from those in the allergic rhinitis study. The strain name alone does not make these products interchangeable.

The overall symptom score decreased.

Study findings. The total IBS-SSS symptom score on a 0–500 scale fell by 177.60 points with inactivated HT-ES1 versus 60.44 points with placebo (p < 0.0001).

Studied regimen2.5 billion cells per day, with 50 mg of the preparation in two capsules taken togetherCapsules containing heat-inactivated HT-ES1, strain CECT 7347
Duration and population84 days200 adults aged 18–65 with irritable bowel syndrome with diarrhea, of whom 197 had data after starting the regimen

Comparator — capsules containing maltodextrin and none of the bacteria under study

Overall constipation score in older adults — BB5362/4 LowRead moreCollapse
Confidence
2/4 LowThe trial included 80 older adults, of whom 79 were analyzed. It assessed the overall constipation score. The separate bowel movement frequency subscale changed differently, but its scores cannot be converted into a number of additional bowel movements.

There was no advantage on the overall constipation measure.

Study findings. Over 4 weeks, the change in the total CSS constipation score did not differ significantly from placebo (p = 0.074).

Studied regimenAt least 50 billion CFU per day, taken as one 2 g sachetSachet of powder containing dried live BB536
Duration and population4 weeks80 people aged 65 and older with chronic constipation, including IBS with constipation. The analysis included 79 people, and the mean age was about 78 years.

Comparator — placebo powder without BB536

Perceived stress — NCC30012/4 LowRead moreCollapse
Confidence
2/4 LowA small exploratory trial in which 49 people were assigned to groups and 45 were included in the main analysis. This was a self-reported measure of stress in generally healthy adults. The result does not establish that all anxiety symptoms improved.

Participants reported slightly less stress.

Study findings. The Perceived Stress Scale (PSS) score on a 0–56 scale was 3.28 points lower than with placebo. The 95% confidence interval indicated a reduction of 0.62–5.93 points (p = 0.017).

Studied regimen10 billion CFU per day, taken at breakfast as one sachet dissolved in about 50 mL of waterSachet of powder containing live NCC3001
Duration and population6 weeks49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis

Comparator — powder containing maltodextrin, yeast extract, cysteine, and pea flour, with no NCC3001

Anxiety — NCC30012/4 LowRead moreCollapse
Confidence
2/4 LowAnxiety was assessed as a separate outcome in a small trial of people with elevated stress. The interval includes both a decrease and a small increase in the score, so it does not establish that the two regimens had exactly the same effect.

No difference in anxiety was detected compared with placebo.

Study findings. The difference in HADS-A anxiety scores was −0.65 points (95% confidence interval −2.05 to 0.76 points, p = 0.358).

Studied regimen10 billion CFU per day, taken at breakfast as one sachet dissolved in about 50 mL of waterSachet of powder containing live NCC3001
Duration and population6 weeks49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis

Comparator — powder containing maltodextrin, yeast extract, cysteine, and pea flour, with no NCC3001

Overall sleep score — 17142/4 LowRead moreCollapse
Confidence
2/4 LowParticipants reported sleep problems and had no diagnosis of insomnia. Some participants’ sleep complaints had already eased between screening and the start of the regimen. The result applies to this group over 8 weeks.

The overall sleep score did not differ from placebo.

Study findings. After 8 weeks, the total PSQI sleep quality score on a 0–21 scale was 4.0 with strain 1714 versus 4.3 with placebo (p = 0.64). A lower score indicates fewer sleep problems.

Studied regimen1 billion CFU per day, taken as one capsule in the morning with or after foodCapsule containing live strain 1714
Duration and population8 weeks89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia.

Comparator — capsule containing corn starch and magnesium stearate, with no 1714

Overall sleep score — NCC30012/4 LowRead moreCollapse
Confidence
2/4 LowSleep was assessed as an additional outcome in a small trial of people with stress. Many did not have substantial sleep problems at baseline. The conclusion applies to the total PSQI score. A separate rating of subjective sleep quality cannot substitute for this measure.

The overall sleep score did not differ from placebo.

Study findings. The difference in total PSQI scores was −0.38 points (95% confidence interval −1.13 to 0.37 points, p = 0.308).

Studied regimen10 billion CFU per day, taken at breakfast as one sachet dissolved in about 50 mL of waterSachet of powder containing live NCC3001
Duration and population6 weeks49 healthy adults aged 25–65 with mild or moderate stress, of whom 45 were included in the main analysis

Comparator — powder containing maltodextrin, yeast extract, cysteine, and pea flour, with no NCC3001

Sleep measured by a wrist-worn device — 17142/4 LowRead moreCollapse
Confidence
2/4 LowThe wrist-worn device estimated sleep from movement, separately from the questionnaire responses. The p-values for the four measures were 0.95, 0.29, 0.69, and 0.34. The trial did not study treatment for diagnosed insomnia.

Measurements taken with instruments did not show an advantage.

Study findings. In weeks 5–8, the percentage of time spent asleep was 92% with strain 1714 versus 91% with placebo. The device recorded an average of 15 versus 16 awakenings. Differences in these measures, in time to fall asleep, and in time spent awake after falling asleep were not statistically significant.

Studied regimen1 billion CFU per day, taken as one capsule in the morning with or after foodCapsule containing live strain 1714
Duration and population8 weeks89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia.

Comparator — capsule containing corn starch and magnesium stearate, with no 1714

Individual sleep complaints at 4 weeks — 17141/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThese are individual components of the questionnaire, separate from its overall score. The researchers tested many measures at the same time, increasing the likelihood of a chance finding. At eight weeks, there was no sustained advantage on these questionnaire components.

The early differences were no longer statistically significant after adjustment for multiple comparisons.

Study findings. At 4 weeks, sleep quality scores were 1.0 versus 1.2 points with placebo, and daytime difficulty scores were 0.5 versus 0.7 points with placebo, on 0–3 scales. These differences were no longer statistically significant after adjustment for multiple comparisons.

Studied regimen1 billion CFU per day, taken as one capsule in the morning with or after foodCapsule containing live strain 1714
Duration and population8 weeks89 adults aged 18–45 with sleep complaints, of whom 87 were included in the analysis. None had diagnosed insomnia.

Comparator — capsule containing corn starch and magnesium stearate, with no 1714

Visual memory and learning — 17141/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOnly 20 male students completed both periods, out of 30 participants assigned to groups. Repeated testing itself improves performance. A change within a single period does not establish an effect of the supplement.

There was no advantage on the visual memory task.

Study findings. At the end of the supplementation period, the mean number of errors on the PAL task was 2.30 with 1714 and 2.42 with placebo. No statistically significant difference was found.

Studied regimen1 billion CFU per day, taken as one capsule in the morningCapsule containing live strain 1714
Duration and populationTwo periods of approximately 8 weeks each, timed to coincide with exams30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years.

Comparator — An identical capsule containing corn starch and magnesium stearate, without 1714

Sustained attention — 17141/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThis was a very small trial of male students during exams. Twenty participants completed both periods. Performance also improved with repeated testing without the supplement. The result cannot be generalized to all types of attention.

There was no advantage on the attention task.

Study findings. At the end of the supplementation period, the mean number of correctly detected signals on the RVP test was 23.80 with 1714 and 23.30 with placebo. No statistically significant difference was found.

Studied regimen1 billion CFU per day, taken as one capsule in the morningCapsule containing live strain 1714
Duration and populationTwo periods of approximately 8 weeks each, timed to coincide with exams30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years.

Comparator — An identical capsule containing corn starch and magnesium stearate, without 1714

Emotion recognition — 17141/4 Very lowRead moreCollapse
Confidence
1/4 Very lowThe study was small and had substantial dropout. Twenty male students completed both periods. The study measured performance on a specific computer task. The ability to understand other people more broadly was outside its scope.

There was no advantage in emotion recognition.

Study findings. The proportion of correct responses on the ERT emotion recognition test was 78.19% with 1714 and 77.56% with placebo. No statistically significant difference was found.

Studied regimen1 billion CFU per day, taken as one capsule in the morningCapsule containing live strain 1714
Duration and populationTwo periods of approximately 8 weeks each, timed to coincide with exams30 male students were assigned to groups and 20 completed both periods. The mean age was about 21 years.

Comparator — An identical capsule containing corn starch and magnesium stearate, without 1714

Depressive symptoms on the Beck Depression Inventory — 17142/4 LowRead moreCollapse
Confidence
2/4 LowThis was the primary outcome in a trial of people with mild or moderate depressive symptoms. The interval includes the possibility of no difference. The finding applies to the Beck Depression Inventory. It does not combine the mood measures that were assessed separately.

The primary outcome did not differ from placebo.

Study findings. At 8 weeks, the between-group difference in BDI-II score change was −1.43 points (95% confidence interval −3.30 to 0.44 points, p = 0.132).

Studied regimen10 billion CFU per day, taken as two capsules containing 5 billion CFU eachCapsules containing live strain 1714
Duration and population8 weeks168 adults aged 18–70 with mild or moderate depressive symptoms. Eligibility required meeting criteria for a depressive disorder.

Comparator — Capsules containing corn starch and magnesium stearate, without 1714

Allergic rhinitis during usual medication use — HT-ES12/4 LowRead moreCollapse
Confidence
2/4 LowThis was a small trial. The primary analysis included 25 people in the HT-ES1 group and 22 in the placebo group. Four weeks after stopping the supplement, the difference was no longer statistically significant. The result was observed when HT-ES1 was used alongside usual medications.

The combined symptom and medication use score decreased.

Study findings. At 8 weeks, the total CSMS on a 0–6 scale was 0.60 points lower than with placebo (95% confidence interval for the reduction 0.09–1.12 points, p = 0.022). The score accounts for both symptoms and medication use.

Studied regimen2 billion cells per day, equivalent to 20 mg of material in two capsules taken togetherCapsules containing heat-inactivated HT-ES1, strain CECT 7347
Duration and population8 weeks of supplementation followed by 4 more weeks of observation without the supplement72 adults aged 18–60 with moderate or severe allergic rhinitis. Of these, 64 began taking their assigned capsules and were included in the primary analysis.

Comparator — Maltodextrin capsules. All groups continued their usual rhinitis medications.

Allergic rhinitis during usual medication use — live ES12/4 LowRead moreCollapse
Confidence
2/4 LowSeven people dropped out of the live ES1 group before taking any capsules. The primary analysis included 17 people in the ES1 group and 22 in the placebo group. The small group limits the precision of the estimate. The result for inactivated HT-ES1 cannot be attributed to live ES1.

No advantage was found on the overall score.

Study findings. Live ES1 showed no statistically significant advantage over placebo on the combined symptom and medication use score (CSMS) at either the 8-week assessment or the assessment 4 weeks after supplementation ended.

Studied regimen2 billion CFU per day, taken as two capsules togetherCapsules containing live ES1, strain CECT 7347
Duration and population8 weeks of supplementation followed by 4 more weeks of observation without the supplement72 adults aged 18–60 with moderate or severe allergic rhinitis. Of these, 64 began taking their assigned capsules and were included in the primary analysis.

Comparator — Maltodextrin capsules. All groups continued their usual rhinitis medications.

Body weight — BL212/4 LowRead moreCollapse
Confidence
2/4 LowThe analysis included 66 of the 72 participants with overweight or obesity. This short trial of a specific strain did not establish a weight-loss advantage.

No additional weight loss was detected.

Study findings. Over 8 weeks, body weight decreased by 1.22 kg with BL21 and 0.98 kg with placebo. The difference in weight loss was 0.24 kg (p = 0.57), which was not statistically significant.

Studied regimen20 billion CFU per day, taken as one 3 g sachetPowder containing live BL21 and maltodextrin in a sachet
Duration and population8 weeks72 adults aged 18–65 with overweight or obesity, of whom 66 were included in the analysis

Comparator — 3 g of maltodextrin per day, without BL21

Body mass index — APC14722/4 LowRead moreCollapse
Confidence
2/4 LowIn the human trial, participants took this strain for 12 weeks. Their baseline BMI was 28–34.9 kg/m². The same publication also reports animal experiments. The weight findings from those experiments cannot be generalized to the human trial participants.

No additional reduction in BMI was detected.

Study findings. The between-group difference in BMI change was 0.03 kg/m², with a published 95% confidence interval of −0.4 to 0.3 kg/m². There was no statistically significant difference.

Studied regimen10 billion CFU per day, taken as one capsuleA capsule containing dried live APC1472
Duration and population12 weeks124 adults aged 18–65 with a BMI of 28–34.9 kg/m². BMI results were reported for 122 participants.

Comparator — A maltodextrin capsule without APC1472

Safety and limitations

In healthy people, live probiotics can cause gas and other bowel symptoms. Adverse reactions are also possible with inactivated cells. The HT-ES1 trial reported stomach pain and gas, as well as a possible link to nausea, bloating, and reflux. In people with severe illness or a substantially weakened immune system, live probiotics may increase the risk of infection. In these situations, work with a doctor to choose the product and plan monitoring. The risk is especially important for premature infants. The FDA reported that an infant developed B. longum sepsis and died after receiving a live-bacteria product used in hospital care. This case does not establish how often complications occur in healthy adults. Check the other ingredients as well as the bacteria. For example, the CLA8013 capsule shell in the trial contained pork gelatin and soy lecithin. Other products may have different ingredients.

Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study ↗ · Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study ↗ · Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗ · Probiotics — Fact Sheet for Consumers (NIH ODS) ↗ · Probiotics: Usefulness and Safety (NCCIH) ↗

Interactions

WithEffectActionSource
AntibioticsAntibiotics may reduce the effectiveness of some live probiotics. This depends on the specific antibiotic and bacteria.Check the instructions for your chosen product and ask your doctor or pharmacist whether it is compatible with your prescribed antibiotic.Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet (NIH ODS) ↗

Food sources

B. longum is found in foods with a culture specifically added, such as yogurt with BB536. In the yogurt studied, a daily serving contained about 2 billion CFU of BB536. The study tested whether the bacteria survived, leaving symptom relief unassessed. Check the package for the specific strain, amount per serving, expiration date, and storage instructions. The usual starter cultures in yogurt, kefir, or fermented vegetables do not establish that the specific B. longum strain is present.

Probiotic viability in the gastrointestinal tract in a randomised placebo controlled trial: combining molecular biology and novel cultivation techniques ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study ↗Bowel movement frequency — inactivated CLA8013120 adults aged 20–65 who were prone to constipation, of whom 104 were included in the final analysisCapsules containing heat-inactivated CLA8013. 25 billion cell equivalents per day, taken as one capsule after dinner. Duration 2 weeks. Comparator — A capsule with the same excipients, without CLA8013.Bowel movement frequency increased by 1.16 per week with CLA8013 versus 0.51 per week with placebo. The difference in change was 0.65 bowel movements per week (p = 0.048).
Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT ↗Bowel movement frequency — live BB53624 healthy adults aged 40–60 who had 3–5 or at least 7 bowel movements per weekLive BB536 in microcapsules with an acid-resistant coating. About 5 billion CFU per day, taken as 0.53 g of microcapsules with water. Two 2-week periods separated by a 4-week break. Comparator — Identical microcapsules containing potato starch, without BB536.In week 2, participants averaged 5.38 bowel movements per week with BB536 versus 4.63 with placebo, a difference of 0.75 per week (p = 0.0334).

Sources

Sources
  1. Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study ↗
  2. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT ↗
  3. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study ↗
  4. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome ↗
  5. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome ↗
  6. Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial ↗
  7. Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial ↗
  8. Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial ↗
  9. Improvements in sleep indices during exam stress due to consumption of a Bifidobacterium longum ↗
  10. Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial ↗
  11. Effects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial ↗
  12. Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis ↗
  13. Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study ↗
  14. Bifidobacterium longum counters the effects of obesity: Partial successful translation from rodent to human ↗
  15. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗
  16. Probiotic viability in the gastrointestinal tract in a randomised placebo controlled trial: combining molecular biology and novel cultivation techniques ↗
  17. Probiotics — Fact Sheet for Consumers (NIH ODS) ↗
  18. Probiotics: Usefulness and Safety (NCCIH) ↗
  19. Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet (NIH ODS) ↗
  20. The Effects of Bifidobacterium Longum 1714 in a Population With Low Mood — NCT04925440 ↗